The rise in incidence of chronic diseases like cancer has triggered the need of better treatment options. Antibodies have the capacity to strengthen the immunity system to give it a fighting chance.
Antibodies
Antibodies are Y-shaped proteins produced within the immune system to thwart attacks from foreign bodies like viruses. They neutralize these bodies by identifying their antigen and prevent its expansion within the human body. It is also known as immoglobulin (Ig).
Monoclonal (mAbs) and polyclonal (pAbs) antibodies are produced by biopharmaceutical and biotechnology companies on a large scale to aid in treatment of cancer and blood disorders. These Ig’s are created using the serum of animals. But recent technological breakthroughs have resulted in the development of antibody-drug conjugates (ADCs).
Latest Developments
ADCs are advanced antibodies which target foreign or cancerous cells without harming healthy cells. These drugs contain a cytotoxic agent which targets only specified tumor cells. The U.S. Food & Drug Administration (FDA) has approved Genentech’s Kadcyla to treat metastatic breast cancer in 2011.
A novel technology developed by Sutro Biopharma called cell-free protein synthesis can overcome the limitations of cell gene expression systems. It can produce various versions of antibodies to further the development of viable ADCs. The potency of these drugs depend on the purity of mAbs. Other future trends in the market are molecules with bispecific target binding and minimized antibody derived binding moieties.
Market Overview
The worldwide antibody production market is anticipated to touch USD 23 billion by 2025, according to Grand View Research, Inc. It is driven by the increasing demand of antibody therapeutics by biopharmaceuticals. Development of advanced antibodies to treat rheumatic heart disease, arthritis, and cancer is another driving factor spurring market growth.
mAbs segment led the global market in 2016. Downstream processing generated huge revenues for the market in 2016. It is expected to exhibit a significant growth rate over the forecast period due to its utilization of chromatography devices and resins. Asia Pacific is expected a robust growth rate over the forecast period due to favorable regulations regarding antibody production. Key players are INTEGRA Biosciences AG, Merck KGaA, Pall Corp., and Cellab GmbH.
In-Depth research report on antibody production market:
No comments:
Post a Comment